Get to know our clinical trials
Clinical trial to evaluate the efficacy and safety of neoadjuvant immunotherapy combinations in patients with surgically resectable hepatocellular carcinoma (MORPHEUS-NEO HCC).
THE PURPOSE OF THIS STUDY IS TO COMPARE THE EFFECTS, GOOD OR BAD, THAT AIT (ANTINEOPLASTIC IMMUNOTHERAPY) COMBINATIONS HAVE ON YOU AND YOUR LIVER CANCER, TO FIND OUT WHICH TREATMENT IS BEST. THE AIT COMBINATIONS ARE EXPERIMENTAL DRUG TREATMENTS, WHICH MEANS THAT THEY ARE NOT APPROVED BY HEALTH AUTHORITIES FOR THE TREATMENT OF LIVER CANCER AS NEOADJUVANT THERAPY (TREATMENT OF CANCER BEFORE SURGERY).
Technical Summary
- PHASE IB/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, OPEN-LABEL PLATFORM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCELLULAR CARCINOMA (MORPHEUS-NEO HCC). IMMUNOTHERAPY.
- Code EudraCT: 2022-502840-11-00
- Protocol number: GO44457
- Promoter: F. Hoffmann-La Roche Ltd.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.